Imagine a new RTP Company plastic compound technology designed to maintain strength, integrity, and functionality, even after repeated exposure to chemicals used to clean and disinfect medical devices in hospital environments. The new RTP 2000 HC series of thermoplastic compounds are designed to match the physical performance and moldabilty of amorphous polymers such as polycarbonate (PC) and polycarbonate/ABS (PC/ABS) alloys that have traditionally been used in many medical device housings and that are now failing due to chemical attack by more aggressive cleaners and disinfectants used to control the spread of infections in hospitals.
Presented by Josh Blackmore, RTP Company Global Healthcare Manager, and Jesse Dulek, RTP Company Product Development Engineer, this 40 minute webinar will cover the following topics:
- Brief introduction to healthcare industry efforts to control the spread of infection and current chemistries of hospital cleaners used to combat this spread of infection
- How these chemicals are affecting performance of traditional plastics used in medical housings
- Test methods that can be used to replicate molded-in part stress and screen performance of plastics exposed to hospital cleaners
- Introduction to RTP 2000 HC series of plastic compounds that can resist the damage caused by harsh hospital cleaners
- How to use RTP 2000 HC as a drop-in replacement for PC, PC/ABS and other amorphous polymers
- Further enhancing RTP 2000 HC thermoplastic compounds with flame retardant, EMI shielding, UV resistance, and/or color attributes
Download the slides (for Prospector Members only)
The views, opinions and technical analyses presented here are those of the author, and are not necessarily those of UL, ULProspector.com or Knowledge.ULProspector.com. While the editors of this site make every effort to verify the accuracy of its content, we assume no responsibility for errors made by the author, editorial staff or any other contributor. All content is subject to copyright and may not be reproduced without prior authorization from Prospector.